|
WO2021011754A1
|
|
Intestinal alkaline phosphatase-based treatments of metabolic disorders
|
|
WO2020247421A1
|
|
Alkaline phosphatase formulations and uses thereof
|
|
WO2020227263A1
|
|
Alkaline phosphate-based oncology treatments
|
|
WO2020227262A1
|
|
Beta-lactamase compositions for treatment of graft versus host disease
|
|
WO2019245938A1
|
|
Methods of making alkaline phosphatase agents
|
|
US2021023182A1
|
|
Alkaline phosphatase agents for treatment of radiation disorders
|
|
US2021030686A1
|
|
Intestinal alkaline phosphatase formulations
|
|
AU2019207600A1
|
|
Alkaline phosphatase agents for treatment of neurodevelopmental disorders
|
|
EP3600257A1
|
|
Alkaline phosphatase formulations
|
|
US2020108130A1
|
|
Beta-lactamase formulations
|
|
US2019275120A1
|
|
Methods and compositions for attenuating antibiotic resistance
|
|
CN109562147A
|
|
Protect microorganism group from oral antibiotic
|
|
WO2017200876A1
|
|
Anti-methanogenic compositions
|
|
KR20170122776A
|
|
Safe and effective beta-lactamase for microbiome protection
|
|
CN107530406A
|
|
For protecting the carbapenem enzyme being used together with antibiotic of intestines microbial population
|
|
US2016193307A1
|
|
Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
|
|
CA2962959A1
|
|
Beta-lactamase formulations and uses thereof
|
|
AU2015308897A1
|
|
E. coli-based production of beta-lactamase
|
|
AU2014201082A1
|
|
Modified beta-lactamases and methods and uses related thereto
|
|
AU2011257092A1
|
|
Modified beta-lactamases and methods and uses related thereto
|
